OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today announced the appointment of Jennifer R. Diamond, M.D., as Chief Medical Officer. Dr. Diamond, a trained oncologist, brings over 10 years of extensive clinical expertise in early phase trials and translational oncology research.
“We are very pleased to welcome Jennifer to our growing leadership team,” said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure. “Her vast knowledge of conducting early-stage trials for novel oncology therapeutics, as well as her experience exploring novel combination strategies, will be vital as we continue to build and advance our broad pipeline of best-in-class precision medicines.”
In addition to serving in her role at OnKure, Dr. Diamond works in the Division of Medical Oncology at the University of Colorado Anschutz Medical Campus as a breast cancer medical oncologist and Associate Professor of Medicine. She is also the Clinical Research Director of the Phase 1 and Expansion/Molecular Studies Program (POEMs) and the founding Co-Director of the Women’s Cancer Developmental Therapeutics Program at the CU Cancer Center. Dr. Diamond has been involved in clinical and translational research in the Phase 1 and Breast Cancer research programs at CU since 2007 and currently runs a research laboratory focused on the development of targeted agents in TNBC, including strategies to overcome treatment resistance. She received her B.A. from the University of Arizona and her M.D. from the University of Arizona College of Medicine. Dr. Diamond completed her fellowship in Medical Oncology at CU under Dr. Gail Eckhart.
“I am thrilled to be joining OnKure at such an important time in the Company’s growth,” said Dr. Diamond. “OnKure’s proven structure-based drug design approach has the potential to create optimal, tumor-agnostic treatments for cancer patients with high unmet need. I look forward to leveraging my experiences to lead the Company’s clinical development efforts and advance its promising lead candidate, OKI-179, as well as future oncology programs in the clinic.”
About OnKure Therapeutics
OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. Using its proven structure-based drug design approach, the Company is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate, OKI-179, an oral, selective Class 1 HDAC inhibitor, for the treatment of both hematological and solid tumors, with plans to initiate a Phase 2 combination trial with binimetinib in NRAS melanoma in 2022.
For more information about OnKure, please visit www.onkuretherapeutics.com.